These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28215728)

  • 1. Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Poston KL
    Parkinsonism Relat Disord; 2017 May; 38():31-34. PubMed ID: 28215728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes.
    Mills KA; Mari Z; Pontone GM; Pantelyat A; Zhang A; Yoritomo N; Powers E; Brandt J; Dawson TM; Rosenthal LS
    Parkinsonism Relat Disord; 2016 Dec; 33():107-114. PubMed ID: 27733275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.
    Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
    Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease.
    Benge JF; Balsis S; Madeka T; Uhlman C; Lantrip C; Soileau MJ
    Parkinsonism Relat Disord; 2017 Aug; 41():104-108. PubMed ID: 28572020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Domain specific cognitive impairment in Parkinson's patients with mild cognitive impairment.
    Chaudhary S; Kumaran SS; Kaloiya GS; Goyal V; Sagar R; Kalaivani M; Jaganathan NR; Mehta N; Srivastava A
    J Clin Neurosci; 2020 May; 75():99-105. PubMed ID: 32192853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
    Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
    PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Zabetian CP; Quinn J; Edwards KL; Leverenz JB; Montine T; Cholerton B; Poston KL
    Mov Disord; 2019 Feb; 34(2):285-291. PubMed ID: 30776152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease.
    Gill DJ; Freshman A; Blender JA; Ravina B
    Mov Disord; 2008 May; 23(7):1043-1046. PubMed ID: 18381646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation.
    Godefroy O; Fickl A; Roussel M; Auribault C; Bugnicourt JM; Lamy C; Canaple S; Petitnicolas G
    Stroke; 2011 Jun; 42(6):1712-6. PubMed ID: 21474808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.
    Zadikoff C; Fox SH; Tang-Wai DF; Thomsen T; de Bie RM; Wadia P; Miyasaki J; Duff-Canning S; Lang AE; Marras C
    Mov Disord; 2008 Jan; 23(2):297-9. PubMed ID: 18044697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The test accuracy of the Montreal Cognitive Assessment (MoCA) by stroke lateralisation.
    Chan E; Altendorff S; Healy C; Werring DJ; Cipolotti L
    J Neurol Sci; 2017 Feb; 373():100-104. PubMed ID: 28131163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Montreal Cognitive Assessment (MoCA) identify cognitive impairment profiles in Parkinson's disease? An exploratory study.
    Castelli MB; Alonso-Recio L; Carvajal F; Serrano JM
    Appl Neuropsychol Adult; 2024; 31(3):238-247. PubMed ID: 34894908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. French consensus procedure for assessing cognitive function in Parkinson's disease.
    Dujardin K; Auzou N; Lhommée E; Czernecki V; Dubois B; Fradet A; Maltete D; Meyer M; Pineau F; Schmitt E; Sellal F; Tison F; Vidal T; Azulay JP; Welter ML; Corvol JC; Durif F; Rascol O;
    Rev Neurol (Paris); 2016 Nov; 172(11):696-702. PubMed ID: 27318613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.
    Nazem S; Siderowf AD; Duda JE; Have TT; Colcher A; Horn SS; Moberg PJ; Wilkinson JR; Hurtig HI; Stern MB; Weintraub D
    J Am Geriatr Soc; 2009 Feb; 57(2):304-8. PubMed ID: 19170786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional Queen Square (QS) screening items improve the test accuracy of the Montreal Cognitive Assessment (MoCA) after acute stroke.
    Chan E; Garritsen E; Altendorff S; Turner D; Simister R; Werring DJ; Cipolotti L
    J Neurol Sci; 2019 Dec; 407():116442. PubMed ID: 31677556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underestimation of cognitive impairments by the Montreal Cognitive Assessment (MoCA) in an acute stroke unit population.
    Chan E; Khan S; Oliver R; Gill SK; Werring DJ; Cipolotti L
    J Neurol Sci; 2014 Aug; 343(1-2):176-9. PubMed ID: 24880539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CERAD test performance and cognitive impairment in Parkinson's disease.
    Karrasch M; Laatu S; Martikainen K; Marttila R
    Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computerized testing in Parkinson's disease: Performance deficits in relation to standard clinical measures.
    Flannery SL; Jowett T; Garvey A; Cutfield NJ; Machado L
    J Clin Exp Neuropsychol; 2018 Dec; 40(10):1062-1073. PubMed ID: 29978753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.